Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A

Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A

The FDA-approved EGFR/HER2 inhibitor varlitinib inhibits tumor growth and is used in cancer treatment. However, the neuroinflammatory response associated with EGFR/HER2 and its underlying mechanism have not been elucidated. This study evaluates the impact of varlitinib on LPS- and tau-mediated neuro...

Full description

Bibliographic Details
Main Authors: Jieun Kim, Su-Jin Kim, Ha-Ram Jeong, Jin-Hee Park, Minho Moon, Hyang-Sook Hoe
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
LPS
NLRP3
Akt
microglia
FAK
varlitinib
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.903309/full

Similar Items

Similar Items